A trial natriuretic peptide (ANP), a cardiovascular hormone with natriuretic, diuretic, and vasodilator activity, 1 contributes to the risk of cardiovascular events depending on either abnormal circulating concentrations or peptide structural alterations. 2 In the latter regard, the molecular variant of the prepro-ANP gene characterized by the substitution of thymidine with cytosine in position 2238 affects the incidence of cardiovascular events in different human populations. [2] [3] [4] [5] [6] We recently reported a significant
increase in the incidence of acute coronary syndromes and cardiovascular mortality in subjects carrying the C2238 minor allele (hereafter C2238-MA) from 2 European cohorts of stable angina patients. 6 Furthermore, in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) population, despite high genetic heterogeneity, an association of C2238-MA with the incidence of stroke was observed in a univariate analysis. 7 Diuretic treatment led to optimal blood pressure control and a significant reduction of cardiovascular risk in hypertensive patients carrying C2238-MA, thus suggesting an impaired diuretic effect of this ANP variant. 7 We have demonstrated previously that C2238-αANP inhibits endothelial cell proliferation and tube formation through increased reactive oxygen species (ROS) production in vitro. 8 Taken together, these findings strongly indicate that the C2238-MA carrier status represents a novel genetic cardiovascular risk factor. Of note, C2238-MA frequency ranges from 13% to 23% in the general population, which indicates the large impact that this variant may have. However, the molecular mechanisms underlying the vascular effects of C2238-αANP are currently unknown.
ANP binds preferentially to natriuretic peptide receptor (NPR)-A and NPR-C, whereas NPR-B is mainly bound by C-type natriuretic peptide (CNP), which can also bind NPR-C. NPR-A mediates the ANP-dependent natriuretic, vasorelaxant, and antihypertrophic effects, 1 whereas NPR-B modulates cardiomyocyte growth. 1 Although NPR-C is believed to be mainly a clearance receptor, increasing evidence indicates that NPR-C signaling plays an active role in the regulation of cellular processes during both physiological and pathological conditions. 9 To date, it is not known which receptor mediates the detrimental effects of C2238-αANP.
The aim of the present study was to dissect the molecular mechanisms underlying the vascular effects exerted by C2238-αANP. Here, we provide novel evidence that NPR-C mediates the detrimental actions induced by C2238-αANP in endothelial cells. We consider our results to be clinically relevant because they suggest a novel therapeutic strategy to reduce cardiovascular risk in C2238-MA carriers.
Methods

In Vitro Studies
Commercially available human umbilical vein endothelial cell (HUVEC; Cambrex) and human aortic endothelial cell (HAEC; Lonza) were used within 4 passages for in vitro experiments, and they were cultured in endothelial growth medium-2. Synthetic wild-type (T2238)-and mutant (C2238)-αANP were purchased from Primm. Cell viability and apoptosis were assessed by Trypan blue, annexin V staining (Roche), and immunoblot of cleaved caspase-3. cGMP and cAMP measurements were performed with specific enzyme immunoassay kits (Biotrak System, Amersham), as per the manufacturer's instructions. C2238-and T2238-αANP binding affinity at NPR-C was assessed through the evaluation of their ability to displace biotinylated cANF 4-23 from the NPR-C by fluorescence-activated cell sorter analysis. cANF 4-23 is a specific ligand for NPR-C. In addition, potential interaction energies of the binding of T2238-αANP, C2238-αANP, and CNP with NPR-C were computed. Phospholipase C activity was evaluated by phosphoinositide hydrolysis assay. HUVEC tube formation was studied with matrigel (BD Biosciences), as previously reported. 8 NPR-C was inhibited in vitro by antisense oligonucleotide, purchased from Life Technologies and used as per the conditions described by Palaparti et al. 10 Alternatively, NPR-C gene silencing with small interfering RNAs (Sigma) was performed. Pertussis toxin (PTX) was used to inhibit Giα protein, whereas forskolin was used to activate adenylate cyclase. Protein kinase A (PKA) was inhibited by H89, whereas nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase was inhibited by apocynin; all reagents were purchased from Sigma Aldrich. Adenovirus expressing constitutively active Akt1 was used to activate Akt1. Adenovirus expressing β-galactosidase was used as control. Recombinant adenovirus vectors were constructed, propagated, and titered as previously reported. 11
Ex Vivo and In Vivo Studies
Rat isolated mesenteric resistance arteries were used to test the effect of C2238-αANP on endothelium-dependent and -independent vascular responses in the presence and absence of selective pharmacological NPR-C blockade by M372049, as previously described. 9 Flow-mediated dilation was measured, according to recent guidelines, 12 in 3 groups of young healthy subjects, matched for age and sex and free of cardiovascular risk factors: subjects homozygous for the T2238 wild-type allele (controls, n=10), subjects homozygous for the C2238-MA (n=10), and heterozygous TC2238 subjects (n=15). Each subject gave a written informed consent to participate to the study.
Statistical Analysis
Continuous variables are expressed as mean±SEM. Comparisons between 2 groups were performed using Student t test. When the analysis was adjusted for the multiplicity of compared groups, 1-way ANOVA followed by Bonferroni post hoc test was performed. Normality of variable distribution was tested by Kolmogorov-Smirnov test. GraphPad Software (San Diego, CA, version 5.0) and SPSS statistical software (SPSS Inc, Chicago, IL, version 12.0) were used for statistical analysis. A P<0.05 was considered significant. An expanded version of the Methods section is available in the online Data Supplement file.
Results
C2238-αANP Is Associated With Increased Endothelial Cell Death and Apoptosis
We hypothesized that C2238-αANP reduces HUVEC survival. After 48 hours, both 10 -11 mol/L and 10 -9 mol/L C2238-αANP concentrations were associated with a significant reduction of HUVEC number ( Figure 1A ; Online Figure IA ) as compared with both control and T2238-αANP, thus indicating that C2238-αANP may either affect proliferation or survival of HUVEC in vitro. C2238-αANP was also associated with a significant increase in cell death ( Figure 1B ; Online Figure  IB and IC). In contrast, T2238-αANP did not affect HUVEC survival ( Figure 1A and 1B). Apoptosis was also increased in HUVEC exposed to C2238-αANP ( Figure 1C and 1D). Therefore, C2238-αANP directly reduces HUVEC survival and increases apoptosis in vitro. 
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C2238-αANP Is Associated With Endothelial Cell Impairment Through Stimulation of NPR-C and Inhibition of the Adenylate Cyclase/cAMP System
We investigated which NPR mediates the detrimental effects of C2238-αANP. NPR-A and NPR-B are coupled to the guanylate cyclase/cGMP system, thereby increasing cGMP intracellular levels on activation. 1 Increasing concentrations of T2238-αANP and C2238-αANP similarly increased intracellular levels of cGMP ( Figure 2A ). This result excludes that C2238-αANP differentially modulates NPR-A and -B, further confirming our previous observations. 8 In contrast, we found a significant progressive reduction of intracellular cAMP levels on short (30 minutes) stimulation with increasing concentrations of C2238-αANP, as compared with both control and T2238-αANP. The latter stimulated cAMP levels ( Figure 2B ), consistently with previous evidence. 13 This observation indicates an activation of NPR-C by C2238-αANP, because active NPR-C leads to reduction of cAMP intracellular levels through activation of Giα and inhibition of adenylate cyclase. 14 Remarkably, inhibition of NPR-C (Online Figure II) , as well as inhibition of Giα protein by PTX, significantly restored cAMP intracellular concentration in HUVEC exposed to C2238-αANP ( Figure  2C ). Finally, our binding assays revealed that C2238-αANP displaced cANF, 4-23 which selectively binds NPR-C, more strongly than T2238-αANP ( Figure 2D -2F), as indicated by lower dissociation constant (0.36±0.12 nmol/L for C2238-αANP versus 0.96±0.23 nmol/L for T2238-αANP, P<0.01) and higher B max (8605±387 sites per cell/nmol/L for C2238-αANP versus 7825±660 sites per cell/nmol/L for T2238-αANP, P<0.01). No cANF 4-23 displacement from NPR-C was observed with insulin coincubation, which was used as negative control. Consistent results were obtained through in silico computational analysis comparing the potential interaction energies of the binding between T2238-αANP or C2238-αANP or CNP and NPR-C (Online Table I ), which showed that C2238-αANP has the highest affinity for the receptor. Overall, these data indicate that C2238-αANP significantly activates NPR-C, and it binds NPR-C with a higher affinity than T2238-αANP. Of note, no significant changes in the activity of phospholipase C were observed on HUVEC exposure to either C2238-αANP or T2238-αANP (T2238-αANP, 1.8±0.8; C2238-αANP, 1.9±0.7 fold versus baseline; P=NS), thus suggesting no changes in Gβγ subunit activity.
We hypothesized that C2238-αANP exerts its detrimental vascular effects through NPR-C signaling. Consistently, NPR-C inhibition abolished the effects of C2238-αANP on HUVEC number ( Figure 3A ) and death ( Figure 3B ) without affecting survival at baseline (data not shown). NPR-C knockdown by NPR-C-targeted small interfering RNA also restored viability and reduced cell death in HUVEC exposed to C2238-αANP (Online Figure III) . Similar results were observed after PTX treatment (Online Figure IVA) . Reactivation of adenylate cyclase abolished the detrimental effects of C2238-αANP on HUVEC survival ( Figure 3A and 3B). The reduction of vasculogenic properties of HUVEC by C2238-αANP was rescued by NPR-C inhibition and by restoration of cAMP levels ( Figure 3C and 3D), which did not show any effect on tube formation at baseline (data not shown). Similar effects were observed after PTX treatment (Online Figure IVB) . We also validated our results in another cellular model. We found that C2238-αANP reduced HAEC number, increased HAEC death, and impaired HAEC vascular tube formation. All these detrimental effects induced by C2238-αANP were prevented by NPR-C knockdown (Online Figure V) . 
Activation of the NPR-C/Giα/cAMP System by C2238-αANP Affects Endothelial Cell Survival and Angiogenetic Properties Through Inhibition of Akt Signaling and an Increase in Oxidative Stress
We hypothesized that NPR-C activation by C2238-αANP may result in inhibition of Akt1 through inhibition of the cAMP/PKA axis, which positively regulates Akt1. We found that C2238-αANP significantly reduced Akt phosphorylation, a recognized marker of Akt activity ( Figure 4A ). Interestingly, Akt phosphorylation was significantly restored by both NPR-C inhibition and adenylate cyclase activation ( Figure 4A and 4B, Online FigureVI). Remarkably, adenylate cyclase activation failed to activate Akt in the presence of PKA inhibition ( Figure  4B , Online Figure VI) . Accordingly, levels of Akt-dependent phosphorylation of endothelial nitric oxide synthase and Bad (a Bcl-2-related family member) were decreased in HUVEC exposed to C2238-αANP, further indicating inhibition of Akt signaling and suggesting the involvement of Akt inhibition in the reduced survival and function and increased apoptosis of HUVEC exposed to C2238-αANP ( Figure 4C) .
To test the hypothesis that inhibition of Akt1, a master regulator of cell survival, by C2238-αANP is involved in the detrimental effects exerted by C2238-αANP, we reactivated Akt1 in HUVEC in the presence of C2238-αANP (Online Figure VII) , as described in the Methods section. C2238-αANP increased cell death and inhibited vascular cord formation in control HUVEC, but failed to exert its detrimental effects in HUVEC expressing a constitutively active Akt1 ( Figure  4D-4F) .
We have previously shown that C2238-αANP promotes NADPH-dependent ROS production in HUVEC. 8 We evaluated whether NPR-C is involved in these effects. NADPH oxidase-dependent increase in HUVEC oxidative stress was blunted by NPR-C inhibition ( Figure 5A ). Basal expression level of gp91 phox subunit of NADPH was also reduced by NPR-C inhibition ( Figure 5B ). Moreover, inhibition of NADPH oxidase partially inhibited cell death induced by C2238-αANP ( Figure 5C ). However, apocynin failed to significantly rescue Akt inhibition induced by C2238-αANP ( Figure 5D ). These results suggest that NPR-C-dependent ROS production also contributes to the detrimental vascular effects exerted by C2238-αANP independently of Akt1 inhibition.
C2238-αANP Causes Endothelial Dysfunction In Vivo Through NPR-C-Dependent Mechanisms
We hypothesized that C2238-αANP affects endothelial function through NPR-C ex vivo. C2238-αANP induced blunted vasodilation of rat mesenteric vascular rings as compared with T2238-αANP ( Figure 6A ). C2238-αANP also impaired vasorelaxant responses to CNP, which is known to induce vasodilation through NPR-C activation 15 (Figure 6B ). Furthermore, C2238-αANP impaired vascular responses to acetylcholine ( Figure 6C ). Selective pharmacological inhibition of NPR-C prevented the impairment of acetylcholine vascular responses in mesenteric arteries incubated with C2238-αANP ( Figure  6D) . In contrast, vascular responses to spermine-nitric oxide complex hydrate were preserved in the presence of C2238-αANP (Online Figure VIII) . These data indicate that C2238-αANP induces endothelial dysfunction ex vivo through NPR-C-dependent mechanisms.
Importantly, we found that C2238-αANP induces endothelial dysfunction in humans. In fact, in a group of young healthy subjects free of cardiovascular risk factors (Online Table II ), C2238-MA carriers (both heterozygous and homozygous) presented a significant reduction in endothelium-dependent flow-mediated dilation as compared with controls ( Figure 7A ). No differences were observed in the endothelium-independent vasodilation ( Figure 7B ). Figure IV . n=5. C, HUVEC were exposed to regular medium, T2238-αANP (wild type [WT]) or C2238-αANP (Mut), and phosphrorylation statuses of endothelial nitric oxide synthase (eNOS) and Bad were evaluated. Representative immunoblots are shown. D-F, HUVEC were transduced with an adenovirus (10 mois) overexpressing constitutively active Akt1 (Akt) or β-galactosidase (LacZ) for 48 hours. HUVEC were then treated with Mut or control (normal medium, CT) for 12 hours. Cell death (D) and vascular cord formation were evaluated (E and F). Representative images and relative vascular cord quantification are presented at magnification ×2.5. n=6. Figure 5 . C2238-α atrial natriuretic peptide (ANP) induces natriuretic peptide receptor (NPR)-C-dependent oxidative stress. A, Reactive oxygen species production in human umbilical vein endothelial cell (HUVEC) exposed to regular medium (CT) or to C2238-αANP (Mut), pretreated with NPR-C sense (S) or antisense (AS) oligonucleotides. n=4. B, Expression levels of Gp91phox have been evaluated in HUVEC exposed to regular medium or C2238-αANP (Mut), with or without NPR-C AS. Representative immunoblot is presented. C, Cell death was assessed in HUVEC exposed to regular medium, Mut or Mut plus apocynin (APO) and expressed as fold vs CT. n=4. D, Phosphorylation status of Akt1 (serine 473) was evaluated in HUVEC exposed to regular medium, T2238-αANP (wild type [WT]) or C2238-αANP (Mut), with or without APO. Representative immunoblot is presented. DCHF indicates 5-(and-6)-Carboxy-2',7'dichlorofluorescein ester.
Discussion
We demonstrate that a molecular variant of human ANP, C2238-αANP, reduces endothelial cell survival, increases apoptosis, and impairs endothelial cell growth in vitro. In addition, C2238-αANP inhibits endothelium-dependent vasorelaxation ex vivo and induces endothelial dysfunction in humans in vivo. This spectrum of detrimental cardiovascular actions is underpinned by inappropriate NPR-C/Giα signaling.
The frequency of the C2238-MA ranges from 13% to 23% in the general population. It does not affect circulating NT-proANP/ANP levels, 2,6 but rather it results in a structural alteration of the mature peptide by the addition of 2 arginines at the carboxy-terminal end of its primary structure. This ANP variant affects the incidence of cardiovascular events. [2] [3] [4] [5] [6] [7] Notably, C2238-MA does not exert any effect on the development and progression of atherosclerosis, 6 whereas it increases the risk of plaque rupture, cerebrovascular events, acute coronary syndromes, and mortality. [4] [5] [6] [7] In our recent study, C2238-MA was significantly associated with the risk of acute coronary syndrome and it significantly predicted the occurrence of major adverse cardiovascular events and mortality in patients with stable angina from 2 large European populations. 6 Here, we demonstrate for the first time that C2238-αANP directly affects HUVEC survival and angiogenetic properties in vitro, and causes endothelial dysfunction in vivo through NPR-C-dependent mechanisms. It is known that ANP binds to all 3 types of NPRs with a significantly higher (>3 orders of magnitude) affinity for NPR-A than NPR-B. 1 These NPRs are coupled to the guanylate cyclase/cGMP system. In contrast, NPR-C, a clearance receptor of all natriuretic peptides, contains a 37-aa cytoplasmic domain with a Gα inhibitoryprotein-activating sequence that negatively regulates the adenylate cyclase/cAMP system. 14 We found that NPR-A and NPR-B were not differentially modulated by C2238-αANP, thus corroborating our previous evidence. 8 T2238-αANP increased intracellular cAMP, consistent with recent evidence indicating that protein kinase G inhibits phosphodiesterase 3-mediated cAMP proteolysis. 13 In contrast, intracellular concentrations of cAMP were significantly reduced by C2238-αANP at all tested concentrations, consistent with NPR-C activation. Accordingly, reduction of cAMP levels on exposure to C2238-αANP was abrogated by inhibition of NPR-C, as well as by the Giα inhibitor PTX. Our competitive binding experiments also revealed an affinity binding of C2238-αANP to NPR-C significantly higher than that of T2238-αANP. The in silico binding studies also supported these observations. More importantly, either inhibition of NPR-C by AS oligonucleotide or NPR-C knockdown by RNA silencing rescued C2238-αANP-induced HUVEC death. Remarkably, we observed that C2238-αANP reduced survival and affected vasculogenic properties of HAEC. NPR-C knockdown was able to reverse the deleterious effects exerted by C2238-αANP also in these cells, thus extending our observations to a more clinically relevant endothelial cell type.
These findings provide striking evidence of the involvement of inappropriate activation of NPR-C in mediating the detrimental vascular effects of C2238-αANP, and indirectly support our previous work demonstrating that a preserved and physiological activity of NPR-C is required for normal vascular homeostasis. 9, 15 Physiological activation of NPR-C by the endogenous ligand CNP is crucial for maintaining endothelial integrity and promoting cell proliferation. 9, 15 In contrast, supraphysiological activation of NPR-C by cANF [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] has been shown to exert antigrowth properties in vascular smooth muscle cells through inhibition of cAMP and Akt. 16, 17 The remarkable difference in intracellular cAMP levels achieved after exposure of HUVEC to C2238-αANP versus wild-type T2238-αANP suggests that mutant ANP activates NPR-C in a unique, dysregulated manner that is detrimental. We speculate that the detrimental effects of NPR-C activation by C2238-αANP may be explained either by an excessive activation of the receptor or by an imbalance between NPR-C activation and activation of other NPRs. In addition, we propose that a deregulated activation of NPR-C by C2238-αANP may be explained either by its increased affinity for the receptor, or by unknown intrinsic properties of the peptide, which alter NPR-C conformation.
In fact, we demonstrate that C2238-αANP shows an increased affinity for NPR-C. In addition, our in silico calculations, showing higher potential interaction energy of the binding between C2238-αANP and NPR-C, with respect to the NPR-C binding with T2238-αANP or CNP, support the hypothesis that C2238-αANP activates NPR-C in a unique manner.
Our data suggest that deregulated activation of NPR-C by C2238-αANP is detrimental through inhibition of Akt1. cAMP positively regulates PKA, which in turn directly activates Akt signaling in endothelial cells. 18, 19 Akt inhibition in endothelial cells is associated with endothelial damage and dysfunction. 20, 21 We found that activation of NPR-C inhibited Akt signaling through inhibition of the cAMP/PKA axis. In addition, Akt reactivation was able to counteract the detrimental effects exerted on cell survival by C2238-αANP and rescue the angiogenetic properties of HUVEC.
We also observed that C2238-αANP exerts detrimental effects through NPR-C-dependent activation of NADPH oxidase and ROS production, independently of Akt1 inhibition. We speculate that the NPR-C-dependent activation of NADPH oxidase could be the consequence of lower cAMP levels, which have been previously shown to activate NADPH oxidase. 22 Of note, previous evidence indicated that NPR-C activation by cANF 4-23 reduces ammonium chloride-induced ROS production in astrocytes, thus suggesting that the effect of NPR-C activation on ROS accumulation is dependent on the level of receptor activation, on cell type, and on different cellular-stress conditions. 23 C2238-αANP impaired acetylcholine-induced vascular responses in rat isolated resistance arteries, which was rescued by NPR-C pharmacological blockade. We have shown previously that CNP represents an endothelium-derived hyperpolarizing factor, and that many of its vasoprotective actions are mediated via activation of NPR-C. 9, 24 Furthermore, NPR-C activation has been shown to reduce ROS production induced by angiotensin II. 25 Herein, we show that C2238-αANP reduces vasorelaxant activity of both CNP and endotheliumderived hyperpolarizing factor. It is, therefore, likely that the deleterious effects induced by C2238-αANP are dependent, in these circumstances, on the antagonism exerted by C2238-αANP on the physiological activation of NPR-C by CNP.
We extended the in vitro functional observations to isolated vessels in human subjects. Flow-mediated dilation applied in the forearm, and used as an index of endothelial function, leads to a well-characterized and well-studied reactive hyperemia from the vascular endothelium, which seems to be significantly regulated by endothelium-derived hyperpolarizing factor, because subjects with a deficiency of tetrahydrobiopterin (an essential cofactor for synthesis of nitric oxide) have preserved flow-mediated dilation, which is relatively insensitive to nitric oxide synthase inhibitors. 26 In the present study, individuals carrying even 1 variant allele have a significantly reduced reactive hyperaemia (ie, endothelial function), as compared with subjects carrying the wild-type alleles. These data provide proof-of-concept evidence in the human vasculature that impairment of endothelium-derived hyperpolarizing factor bioactivity via NPR-C modulation partially underlies the endothelial dysfunction and associated increased risk of acute coronary events and stroke apparent in subjects carrying C2238-MA. 6 Of note, endothelial dysfunction is a known predictor of cardiovascular diseases, and its restoration is associated with a significant reduction of cardiovascular events. 27
Conclusions
Our study provides the first clear-cut demonstration that C2238-αANP variant reduces endothelial cell survival and impairs endothelial function through binding to NPR-C and interference in the NPR-C/cAMP/Akt signaling pathway ( Figure 7C ).
Our in vitro and ex vivo results strongly suggest that pharmacological targeting of NPR-C represents a potential therapeutic strategy to reduce cardiovascular risk in C2238-MA carriers. Future clinical trials investigating this issue and translating our current results to human subjects are warranted.
